LinkedIn IconTwitter Icon
14-16 November 2017
The Westin Grand Munich, Germany

Day One
Wednesday 15th November, 2017

Day Two
Thursday 16th November, 2017

Chairs Opening Remarks

  • Jannie Borst Head of Division, Immunology, Netherlands Cancer Institute

Keynote – Shifting Paradigms in the Combination Setting

  • Roy Baynes Senior Vice President and Head, Global Clinical Development, Merck Sharp & Dohme


• Understanding why CPIs work so well for some patients with little effect on others
• Exploring the need to utilise this understanding to drive rational, personalised combination treatments that push all patients to an “immune primed” state

Optimising the Tumour Microenvironment

VSV-GP: A Game Changer for Immuno-Oncology

  • Philipp Müller Principal Scientist, Research & Development , Boehringer Ingelheim Pharma GmbH & Co. KG


• Showcasing VSV-GP as a unique platform for a new class of innovative oncolytic virusbased anti-cancer therapeutics
• Revealing the effectiveness of VSV-GP as an IO enabler in the poorly “T-cell inflamed” tumour space for a broad range of cancers
• Highlighting VSV-GP as non-mutagenic virus, which can be armed with additional genes

Functional Programs & Molecular Mechanisms that Optimise Cytotoxic T Cells (CTLs) for Their Anti-Tumour Efficacy

  • Jannie Borst Head of Division, Immunology, Netherlands Cancer Institute


• Outlining the requirements for optimal anti-tumor activity of CTLs on basis of the “Cancer Immunity Cycle”
• Demonstrating in a mouse model of therapeutic vaccination how CD4 T cells optimize primary and memory CD8 T cell responses in magnitude and quality
• Disclosure of key molecular mechanisms that instruct optimal CTL effector function (as identified by transcriptomics in our model) and demonstration of their relevance in anti-tumour immunity

Morning Refreshments & Networking

Assessing Target Synergies: From Design to Delivery

Bispecific TNFR-Superfamily Agonists for Tumour Localised Immune Modulation

  • Shane Olwill Vice President, Development and Head, Immuno-Oncology , Pieris Pharmaceuticals, Inc


• Reviewing the promise for TNFR superfamily as molecular therapeutic targets in cancer
• Highlighting the pitfalls of mAb-based approaches in achieving a tumour-targetdriven activation
• Divulging the benefits for bispecific approaches in increasing the therapeutic window through enhanced peripheral T cell and / or NK cell activation

Combination Strategies for LAG-3Ig (IMP321) With Either Chemotherapy or Anti-PD-1 Therapy


• Understanding the rationale for combining an APC activator (LAG-3Ig) with chemotherapy or an ICI (pembrolizumab)
• Highlighting in vitro and in vivo preclinical data along with emerging clinical data
• Evaluating of the pembrolizumab/LAG-3Ig combination in metastatic melanoma (TACTI-mel phase I trial)

CD47 Neutralising Bispecific Antibodies Promote Adaptive Anti Tumour Immunity


• CD47 is an immune checkpoint controlling both the innate and the adaptive immune responses
• Blockade of tumour-expressed CD47 with bispecific antibodies promotes tumour cell phagocytosis, antigen cross-presentation, and T cell-mediated immunity
• CD47 is expressed ubiquitously bispecific antibodies allow selective blockade of CD47 on tumour cells, which represents an advantage in terms of drug pharmacology and safety as compared to CD47 targeting monoclonal antibodies

Lunch & Networking

Driving an Immune Primed State: Checkpoint Combinations with Standard of Care

Combining Radiotherapy & Immune Modulators

  • Markus Hecht Medical Doctor, Radiology, University Hospital Erlangen
  • Udo Gaipl Head of Radiation Immunobiology, University Hospital Erlangen


• Exploring the rationales and clinical findings for the combination of radiotherapy with checkpoint modulators
• Revealing the mechanistic effects of radiotherapy in tumours
• Understanding scheduling, dosing, timing, and time frame of responses to radioimmunotherapy

Targeted Thorium Conjugates & the Potential of Combination Strategies with ICI


• Exploring the potential of systemic antibody-based radiotherapy to deliver the cell-killing power of alpha-particles specifically to tumour cells
• Introducing the Targeted Thorium Conjugate (TTC) platform – in vitro and in vivo
• Potential link to strategies using combinations with ICI

Rationale From Biological & Clinical Data: Strategies for Combining & Sequencing Checkpoint Inhibitors With Other Agents

  • Lucie Heinzerling Head of Dermatooncology and Head of Biomarker Research Group, University Hospital Erlangen


• Combinations of checkpoint inhibitors with other agents have shown promise in improving efficacy
• Chemotherapy, radiotherapy, adjuvants/vaccines and small molecules show immune modulating properties systemically and in the tumour microenvironment
• Analyses of the biological and clinical data gives indications for the way forward

Close of Conference